Chemed Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chemed in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Chemed stock.
View analyst ratings for Chemed or view top-rated stocks.

Wall Street analysts have given Chemed a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Chemed wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Chemed saw a drop in short interest in the month of January. As of January 29th, there was short interest totaling 157,200 shares, a drop of 19.7% from the January 14th total of 195,700 shares. Based on an average daily trading volume, of 90,600 shares, the days-to-cover ratio is currently 1.7 days. Currently, 1.0% of the shares of the stock are sold short.
View Chemed's Short Interest.

Chemed is scheduled to release its next quarterly earnings announcement on Tuesday, April 27th 2021.
View our earnings forecast for Chemed.

Chemed Co. (NYSE:CHE) issued its quarterly earnings data on Monday, February, 22nd. The company reported $5.13 earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of $5.13. The firm earned $533 million during the quarter, compared to the consensus estimate of $537.20 million. Chemed had a trailing twelve-month return on equity of 38.13% and a net margin of 13.11%. The business's revenue was up 2.0% compared to the same quarter last year. During the same period last year, the company earned $4.22 earnings per share.
View Chemed's earnings history.

Chemed's stock was trading at $414.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CHE stock has increased by 4.6% and is now trading at $433.25.
View which stocks have been most impacted by COVID-19.

Chemed announced a quarterly dividend on Friday, February 19th. Stockholders of record on Monday, March 1st will be paid a dividend of $0.34 per share on Friday, March 19th. This represents a $1.36 dividend on an annualized basis and a yield of 0.31%. The ex-dividend date of this dividend is Friday, February 26th.
View Chemed's dividend history.

Chemed pays an annual dividend of $1.36 per share and currently has a dividend yield of 0.32%. Chemed has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Chemed is 9.75%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Chemed will have a dividend payout ratio of 7.51% next year. This indicates that Chemed will be able to sustain or increase its dividend.
View Chemed's dividend history.

Chemed updated its FY21 earnings guidance on Tuesday, February, 23rd. The company provided EPS guidance of $17.00-17.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $17.28.

2 brokers have issued 1-year target prices for Chemed's stock. Their forecasts range from $535.00 to $580.00. On average, they expect Chemed's share price to reach $557.50 in the next twelve months. This suggests a possible upside of 28.7% from the stock's current price.
View analysts' price targets for Chemed or view top-rated stocks among Wall Street analysts.

1 employees have rated Chemed CEO Kevin J. McNamara on Glassdoor.com. Kevin J. McNamara has an approval rating of 100% among Chemed's employees. This puts Kevin J. McNamara in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Chemed include Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), Amedisys (AMED), R1 RCM (RCM), LHC Group (LHCG), AMN Healthcare Services (AMN), MEDNAX (MD), CorVel (CRVL), The Providence Service (PRSC), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Biosciences (IDXG).
View all of CHE's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemed investors own include AT&T (T), The Home Depot (HD), Johnson & Johnson (JNJ), AbbVie (ABBV), Abbott Laboratories (ABT), CVS Health (CVS), The Boeing (BA), UnitedHealth Group (UNH), Verizon Communications (VZ) and Chevron (CVX).

Chemed trades on the New York Stock Exchange (NYSE) under the ticker symbol "CHE."

Chemed's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (9.18%), Wells Fargo & Company MN (3.26%), Riverbridge Partners LLC (2.32%), Renaissance Technologies LLC (1.64%), JPMorgan Chase & Co. (1.58%) and Janus Henderson Group PLC (1.21%). Company insiders that own Chemed stock include Andrea R Lindell, David Patrick Williams, Donald E Saunders, Frank E Wood, George J Walsh III, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Patrick P Grace, Spencer S Lee and Walter L Krebs.
View institutional ownership trends for Chemed.

CHE stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Renaissance Technologies LLC, Aristotle Capital Boston LLC, Squarepoint Ops LLC, First Trust Advisors LP, Citigroup Inc., Skandinaviska Enskilda Banken AB publ , and Keeley Teton Advisors LLC. Company insiders that have sold Chemed company stock in the last year include Donald E Saunders, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Patrick P Grace, and Spencer S Lee.
View insider buying and selling activity for Chemed or view top insider-selling stocks.

CHE stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Wells Fargo & Company MN, JPMorgan Chase & Co., Morgan Stanley, UBS Asset Management Americas Inc., Eaton Vance Management, Eaton Vance Management, and Riverbridge Partners LLC.
View insider buying and selling activity for Chemed or or view top insider-buying stocks.

Shares of CHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CHE stock can currently be purchased for approximately $433.25.

Chemed has a market capitalization of $6.95 billion and generates $1.94 billion in revenue each year. The company earns $219.92 million in net income (profit) each year or $13.95 on an earnings per share basis.

Chemed employs 16,641 workers across the globe.

The official website for Chemed is www.chemed.com.

Chemed is headquartered at 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202.

Chemed's mailing address is 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202. The company can be reached via phone at 513-762-6690.